Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lavinia Anne Spain"'
Autor:
Louise Kathleen Kostos, William Yu Ching Lai, Peter Lambroglou, Elizabeth Medhurst, James Patrick Buteau, Shahneen Sandhu, Ben Tran, Lavinia Anne Spain, Ciara Conduit, Roslyn Wallace, Ramin Alipour, Timothy J. Akhurst, Grace Kong, Anthony Cardin, Javad Saghebi, Aravind Ravi Kumar, Michael S Hofman, Arun Azad
Publikováno v:
Journal of Clinical Oncology. 41:77-77
77 Background: [177Lu]Lu-PSMA (LuPSMA) is currently FDA-approved for use in the post-taxane, post-antiandrogen setting in pts with mCRPC. Little is known about the efficacy of treatment in pts with subsequent progression after LuPSMA. In this single-
Autor:
Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Lavinia Anne Spain, Lisa Horvath, Megan Crumbaker, Angelyn Anton, Roslyn Wallace, Anupama Pasam, Mathias Bressel, Erin Cassidy, Patricia Banks, Nattakorn Dhiantravan, Timothy J. Akhurst, Aravind Ravi Kumar, Ramin Alipour, Mark Scalzo, Scott Williams, Rodney Hicks, Michael S Hofman
Publikováno v:
Journal of Clinical Oncology. 40:5017-5017
5017 Background: The VISION and TheraP trials have established the safety and efficacy of 177Lu-PSMA-617 in mCRPC with a 50% PSA response rate (PSA50-RR) of 46% and 66% and median progression free survival (PFS) of 8.7 and 5.1 months, respectively. M
Autor:
Anis Hamid, Michael S Hofman, Mathias Bressel, Louise Emmett, Anthony M. Joshua, Lavinia Anne Spain, Lisa Horvath, Megan Crumbaker, Anupama Pasam, Jason Callahan, Alisa Tubbs, Luisa Fernandez, Richard J. Wenstrup, Grace Kong, Jeremy Howard Lewin, Ben Tran, Arun Azad, Joseph D. Schonhoft, Rodney J. Hicks, Shahneen Sandhu
Publikováno v:
Journal of Clinical Oncology. 40:5027-5027
5027 Background: The Phase I PRINCE trial (NCT03658447) is evaluating the efficacy of 177Lu-PSMA-617 plus pembrolizumab for mCRPC. The utility of serial monitoring of CTCs and PET as biomarkers of prognosis and clinical benefit of 177Lu-PSMA-617-base